Logo

American Heart Association

  2
  0


Final ID: 4139456

Integrin α5β1 contributes to pathological remodeling of the right ventricle in pulmonary arterial hypertension

Abstract Body (Do not enter title and authors here): Introduction: Right ventricular (RV) function is an important prognosis factor in pulmonary arterial hypertension (PAH). In response to pressure overload, the RV undergoes morphological changes driven by the accumulation of extracellular matrix (ECM) elements and cardiomyocyte hypertrophy. Integrins (Itg) are members of the cell adhesion receptor superfamily. Through ECM-binding, Itg are known to transduce extracellular cues to cardiac cells resulting in the activation of pro-hypertrophic and pro-fibrotic signaling pathways. Among them, integrin α5β1 is one of the most abundant heterodimers in cardiac tissue. We thus hypothesized that α5β1 signaling promotes pathological RV remodeling.

Methods & Results: Using Western blot (WB), we found elevated levels of Itgα5 and Itgβ1 protein in RV isolated from PAH patients compared to controls. Similar findings were observed in monocrotaline (MCT) and pulmonary artery banding (PAB) rats. In adult rat cardiomyocytes, pharmacological inhibition of α5β1 decreased phenylephrine-induced hypertrophy and reversed established hypertrophy induced by MCT treatment (assessment of cell surface area by F-actin labeling). In human RV fibroblasts (RVFB) inhibition of α5β1 prevented TGFβ1-induced activation of control RVFB and decreased proliferation and activation of RVFB derived from PAH patients (WB PCNA, αSMA, COL1; immunofluorescence Ki67). In vivo, inhibition of α5β1 using a small molecule inhibitor or a blocking-antibody improved RV dysfunction (CO, TAPSE, RVFAC, RV strain, as assessed by echocardiography, right heart catheterization and cardiac magnetic resonance imaging) and diminished RV hypertrophy and fibrosis (Fulton index, H&E and Masson’s trichrome staining) in MCT-injected rats with established PAH and PAB rats. Ex vivo, inhibition of α5β1 attenuated cardiomyocyte hypertrophy and RV fibrosis in human precision-cut RV slices exposed to phenylephrine and TGFβ1.

Conclusion: Our results suggest that integrin α5β1 plays a key role in pathological RV remodeling in PAH.
  • Lemay, Sarah-eve  ( Pulmonary Hypertension research group, CRIUCPQ-UL , Quebec , Quebec , Canada )
  • Lippa, Blaise  ( Morphic Therapeutic , Waltham , Massachusetts , United States )
  • Goodwin, Bryan  ( Morphic Therapeutic , Waltham , Massachusetts , United States )
  • Lin, Albert  ( Morphic Therapeutic , Waltham , Massachusetts , United States )
  • Wang, Hua  ( Morphic Therapeutic , Waltham , Massachusetts , United States )
  • Dowling, James  ( Morphic Therapeutic , Waltham , Massachusetts , United States )
  • Lu, Min  ( Morphic Therapeutic , Waltham , Massachusetts , United States )
  • Qiao, Qi  ( Morphic Therapeutic , Waltham , Massachusetts , United States )
  • Mcteague, T. Andrew  ( Morphic Therapeutic , Waltham , Massachusetts , United States )
  • Moy, Terence I.  ( Morphic Therapeutic , Waltham , Massachusetts , United States )
  • Potus, Francois  ( Pulmonary Hypertension research group, CRIUCPQ-UL , Quebec , Quebec , Canada )
  • Montesinos, Monica  ( Morphic Therapeutic , Waltham , Massachusetts , United States )
  • Provencher, Steeve  ( Pulmonary Hypertension research group, CRIUCPQ-UL , Quebec , Quebec , Canada )
  • Boucherat, Olivier  ( Pulmonary Hypertension research group, CRIUCPQ-UL , Quebec , Quebec , Canada )
  • Bonnet, Sebastien  ( Pulmonary Hypertension research group, CRIUCPQ-UL , Quebec , Quebec , Canada )
  • Grobs, Yann  ( Pulmonary Hypertension research group, CRIUCPQ-UL , Quebec , Quebec , Canada )
  • Bourgeois, Alice  ( Pulmonary Hypertension research group, CRIUCPQ-UL , Quebec , Quebec , Canada )
  • Romanet, Charlotte  ( Pulmonary Hypertension research group, CRIUCPQ-UL , Quebec , Quebec , Canada )
  • Sauvaget, Melanie  ( Pulmonary Hypertension research group, CRIUCPQ-UL , Quebec , Quebec , Canada )
  • Breuils Bonnet, Sandra  ( Pulmonary Hypertension research group, CRIUCPQ-UL , Quebec , Quebec , Canada )
  • Theberge, Charlie  ( Pulmonary Hypertension research group, CRIUCPQ-UL , Quebec , Quebec , Canada )
  • Martineau, Sandra  ( Pulmonary Hypertension research group, CRIUCPQ-UL , Quebec , Quebec , Canada )
  • Author Disclosures:
    Sarah-Eve Lemay: DO NOT have relevant financial relationships | Blaise Lippa: DO have relevant financial relationships ; Employee:Morphic Therapeutic:Active (exists now) | Bryan Goodwin: DO have relevant financial relationships ; Employee:Morphic Tx:Active (exists now) ; Individual Stocks/Stock Options:Morphic Tx:Active (exists now) | Albert Lin: No Answer | Hua Wang: No Answer | James Dowling: No Answer | Min Lu: DO have relevant financial relationships ; Employee:Morphic Therapeutic, a wholly owned subsidiary of Eli Lilly and Company:Active (exists now) | Qi Qiao: No Answer | T. Andrew McTeague: No Answer | Terence I. Moy: No Answer | Francois Potus: DO NOT have relevant financial relationships | Monica Montesinos: DO NOT have relevant financial relationships | Steeve Provencher: DO have relevant financial relationships ; Speaker:Janseen:Past (completed) ; Ownership Interest:HVL Therapeutics Inc:Active (exists now) ; Research Funding (PI or named investigator):Sunshine Bio:Active (exists now) ; Research Funding (PI or named investigator):Morphic:Active (exists now) ; Research Funding (PI or named investigator):Esperion:Active (exists now) ; Research Funding (PI or named investigator):Allinaire:Active (exists now) | Olivier Boucherat: DO NOT have relevant financial relationships | Sebastien Bonnet: DO NOT have relevant financial relationships | Yann Grobs: DO NOT have relevant financial relationships | Alice Bourgeois: DO NOT have relevant financial relationships | Charlotte Romanet: DO NOT have relevant financial relationships | Melanie Sauvaget: No Answer | Sandra Breuils Bonnet: DO NOT have relevant financial relationships | Charlie Theberge: DO NOT have relevant financial relationships | Sandra Martineau: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:
More abstracts on this topic:
Biased Activation of RXFP1 signaling via ML290 Attenuates Experimental Pulmonary Hypertension

Sangam Shreya, Brackin Riley, Zeghibe Ana, Shin Elizabeth, Agoulnik Irina, Marugan Juan, Agoulnik Alexander, Rajagopal Sudarshan, Yu Paul, Triantafyllou Georgios, Pham Uyen, Troncone Luca, Yung Lai-ming, Chundi Anand, Darbha Srikrishna, Gipson Gregory, Rajesh Shreyas

Acute Right Ventricular Systolic Dysfunction Diagnosed by Transesophageal Echocardiography in Patients Post-Cardiac Arrest and Undifferentiated Shock: The Role of Clot in Transit Detection

Dieiev Vladyslav, Salinas Pedro

More abstracts from these authors:
Integrin α5β1 represents a novel therapeutic target to improve vascular remodeling in pulmonary arterial hypertension

Lemay Sarah-eve, Theberge Charlie, Martineau Sandra, Lippa Blaise, Goodwin Bryan, Lin Albert, Wang Hua, Dowling James, Lu Min, Qiao Qi, Mcteague T. Andrew, Montesinos Monica, Moy Terence I., Potus Francois, Provencher Steeve, Boucherat Olivier, Bonnet Sebastien, Grobs Yann, Yokokawa Tetsuro, Shimauchi Tsukasa, Romanet Charlotte, Sauvaget Melanie, Breuils Bonnet Sandra, Bourgeois Alice

Exploring P300/CBP as therapeutic approach for right ventricular dysfunction in PAH

Bourgeois Alice, Provencher Steeve, Boucherat Olivier, Bonnet Sebastien, Lemay Sarah-eve, Grobs Yann, Theberge Charlie, Sauvaget Melanie, Martineau Sandra, Gilbert Megan, Breuils Bonnet Sandra, Potus Francois

You have to be authorized to contact abstract author. Please, Login
Not Available